Skip to content

US · INKT · BIOTECHNOLOGY

MiNK Therapeutics, Inc. (INKT) intrinsic value and stock valuation

$8.02as of 2026-11-21 · Mkt cap 58.29M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MiNK Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values INKT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from INKT’s statements →

MiNK Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York City, NY 10010 minktherapeutics.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-12.49M
20192025
Free cash flow
-$-5.93M
20192025
Total equity
-$-14.23M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-12.49M-$-10.65M-$-22.92M-$-30.95M-$-18.61M
Net income-$-12.49M-$-10.78M-$-22.46M-$-27.99M-$-30.21M
EPSd-$-2.93M-$-2.79M-$-6.53M-$-8.31M-$-9.02M
Operating cash flow-$-5.93M-$-9.56M-$-15.76M-$-18.87M-$-12.83M
Capital expenditure$0.00-$0.00-$-70K-$-250K-$-250K
Free cash flow-$-5.93M-$-9.56M-$-15.84M-$-19.12M-$-13.08M
Total assets$14.2M$5.72M$4.55M$21.5M$40.2M
Total debt$5.18M$4.92M$0.00$0.00$0.00
Net debt-$-8.18M$350K-$-3.37M-$-19.64M-$-38.89M
Total equity-$-14.23M-$-19.59M-$-18.06M-$-400K$23.8M
Cash and short-term investments$13.4M$4.58M$3.37M$19.6M$38.9M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$180K$220K$200K$120K$80K
Gross profit-$-180K-$-220K-$-200K-$-120K-$-80K
Research and development expenses$5.76B$6.34M$15.5M$23.1M$14M
Selling, general and administrative expenses$6.73B$4.1M$7.43M$7.71M$4.56M
Other expenses-$-12.48B$0.00-$-200K$0.00$0.00
Operating expenses$12.3M$10.4M$22.7M$30.8M$18.5M
Cost and expenses$12.5M$10.7M$22.9M$31M$18.6M
Interest income$180K$170K$460K$250K$0.00
Interest expense$0.00$0.00$0.00$250K$2.43M
Depreciation and amortization$180K$220K$200K$120K$80K
Ebitda-$-12.31M-$-10.57M-$-22.25M-$-27.87M-$-27.7M
Operating income-$-12.49M-$-10.65M-$-22.92M-$-30.95M-$-18.61M
Total other income/expenses, net-$-10K-$-130K$460K$2.96M-$-11.61M
Income before tax-$-12.49M-$-10.78M-$-22.46M-$-27.99M-$-30.21M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-12.49M-$-10.78M-$-22.46M-$-27.99M-$-30.21M
Weighted average shares outstanding$4.27M$3.74M$3.44M$3.37M$3.35M
Weighted average diluted shares outstanding$4.27M$3.86M$3.44M$3.37M$3.35M
Balance sheet
20252024202320222021
Cash and short-term investments$13.4M$4.58M$3.37M$19.6M$38.9M
Net receivables$0.00$0.00$0.00$0.00$20K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$13.9M$4.99M$3.6M$20.4M$39.6M
Property, plant and equipment, net$390K$730K$950K$1.07M$610K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$390K$730K$950K$1.07M$610K
Total assets$14.2M$5.72M$4.55M$21.5M$40.2M
Accounts payable$3.43M$2.73M$3.91M$5.82M$3M
Short-term debt$5.18M$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$13M$6.96M$11.4M$12.7M$16.5M
Long-term debt$0.00$4.92M$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$15.4M$18.4M$11.2M$9.19M$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$28.5M$25.3M$22.6M$21.9M$16.5M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-156.68M-$-144.18M-$-133.4M-$-110.94M-$-82.95M
Accumulated other comprehensive income (loss)-$-720K-$-630K-$-430K-$-290K-$-630K
Total equity-$-14.23M-$-19.59M-$-18.06M-$-400K$23.8M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$5.18M$4.92M$0.00$0.00$0.00
Net debt-$-8.18M$350K-$-3.37M-$-19.64M-$-38.89M
Cash flow statement
20252024202320222021
Net income-$-12.49M-$-10.78M-$-22.46M-$-27.99M-$-30.21M
Depreciation and amortization$180K$220K$200K$120K$80K
Stock-based compensation$2.67M$1.81M$3.86M$3.03M$1.74M
Change in working capital$3.29M$460K$2.9M$8.77M$3.74M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$690K-$-1.18M-$-1.92M$2.66M-$-150K
Net cash provided by operating activities-$-5.93M-$-9.56M-$-15.76M-$-18.87M-$-12.83M
Investments in property, plant and equipment$0.00$0.00-$-70K-$-250K-$-250K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00-$-70K-$-250K-$-250K
Common stock issued$14.9M$5.8M$0.00$0.00$39.8M
Common stock repurchased$0.00$0.00-$-480K-$-160K$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$14.7M$10.8M-$-410K-$-160K$49.3M
Net change in cash$8.78M$1.21M-$-16.27M-$-19.25M$36.2M
Cash at end of period$13.4M$4.58M$3.37M$19.6M$38.9M
Operating cash flow-$-5.93M-$-9.56M-$-15.76M-$-18.87M-$-12.83M
Capital expenditure$0.00-$0.00-$-70K-$-250K-$-250K
Free cash flow-$-5.93M-$-9.56M-$-15.84M-$-19.12M-$-13.08M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MiNK Therapeutics, Inc.

        MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.

        CEO
        Jennifer S. Buell
        Employees
        15
        Beta
        0.47

        Explore

        Frequently asked questions

        What is the intrinsic value of MiNK Therapeutics, Inc. (INKT)?

        InvestorsCraft does not currently publish an intrinsic value for INKT. How the IC value is calculated.

        Is INKT undervalued?

        InvestorsCraft does not publish an undervaluation signal for INKT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.